Navigation Links
Ranbaxy Gets FDA Approval for Depression Drug

India's drug major Ranbaxy Laboratories has received the US Food and Drug Administration (FDA)'s final approval to manufacture// and market its formulation for the treatment of major depressive disorders in adults.

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly-owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced Friday that FDA approval permitted the Indian company to make Sertraline Hydrochloride tablets in five doses from 25 mg to 200 mg.

FDA's Office of Generic Drugs has determined the Ranbaxy formulation to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Zoloft(r) of Pfizer Pharmaceuticals Inc., it said.

Total annual market sales for Sertraline Hydrochloride Tablets are estimated at $3.07 billion.

'We are pleased to receive this final approval for Sertraline Hydrochloride Tablets. Ranbaxy now offers both solid and liquid dosage forms for this molecule that has established its utility and value in major depressive disorder. This product formulation will be launched immediately,' said Jim Meehan, vice president of Sales and Marketing for RPI.

RPI based in Jacksonville, Florida, is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The company's foray into Novel Drug Delivery Systems has led to proprietary 'platform technologies', resulting in a number of products under development, it said.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
(Date:12/6/2009)... Cambridge have discovered that the loss of a key segment ... the first study to show that this kind of genetic ... Nature . , The study, led by Dr Sadaf ... from the Wellcome Trust Sanger Institute, looked at 300 children ... genome looking for types of mutation known as copy number ...
(Date:12/6/2009)... ORLEANS, Dec. 6 Onyx Pharmaceuticals, Inc. ... data from the pivotal Phase 2b 003-A1 study, ... is well-tolerated in heavily pre-treated relapsed and refractory ... at the ASH/ASCO Joint Symposium at the 51st ... (ASH) in New Orleans. Enrollment in this trial ...
(Date:12/6/2009)... and Treatment site www.sleeping-with-a-sleeping-disorder.com is asking ... or natural sleep aids from around the world ... good cause. The submissions will be compiled in ... by YOU, to be sold from the website ... 100% of the proceeds ,from sales of the ...
(Date:12/5/2009)... There have been significant scientific advances in the ... gain a better understanding of how certain diseases progress ... patients with the best care. Research presented today at ... Hematology explores optimal induction therapies for managing multiple myeloma, ...
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative ... Research presented today at the 51st Annual Meeting ... new treatment options and improved diagnostic methods for ... leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that ...
Breaking Medicine News(10 mins):Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... is related to liver malfunction and now it has another ... scientists it has been found that alcohol consumption is ... types of cancer., ,Scientists found that excessive drinking raises ... and breast. ,As mentioned on the onset that, ...
... is the province which is about 260 km east of ... to prevent the spread of the disease. // ... to stop the spread of the disease. ,Along ... culled deer. ,Totally about eight CWD cases have ...
... put off their sleep for several days at a stretch with ... soon. // ,The ‘24-hour lifestyle’ pills currently under development ... each night. ,The pill promises to deliver sleep that is ... people surviving without sleep for days, reported online edition of The ...
... services were meant to motivate health care workers to go ... According to researchers, these // targets can ... tactics at bay. ,Gwyn Bevan and Christopher Hood ... target based assessment, but have gone further to stress the ...
... a setback, after four private companies took over the reins ... This has created huge problems for patients for whom oxygen ... is estimated that about 60,000 people are in need of ... ,Home deliveries of Oxygen have taken a beating. A ...
... increased level of mercury in some halibut and Pacific ... state wide tests conducted in the fish from grocery ... age should eat only one meal a week of ... guidelines the mercury contamination in the fishes has crossed ...
Other Medicine News:Health News:Rise in Mercury Levels in Supermarket Fish 2
(Date:12/4/2009)... CITY, Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ... to provide therapy equipment and rehab supplies to Benchmark ... Georgia. ,, "We are pleased to be named ... K. Beardall, executive vice president of sales and marketing ...
(Date:12/4/2009)... often stored in tin cans and car trunks ... RetireSafe urged the Senate to defeat the Dorgan Importation plan ... Dorgan,s importation amendment is poised to open our borders, allowing ... health to be endangered. We could soon be getting ...
(Date:12/4/2009)... Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an ... and Drug Administration seeking approval to market its 8mg ... owned by Takeda Pharmaceutical Company Limited. Watson,s 8mg ...
Breaking Medicine Technology:RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Blue Cross Names Three New Executives 59315 1Blue Cross Names Three New Executives 59315 2Blue Cross Names Three New Executives 59315 3PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 5405 1PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 5405 2PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 5405 3PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 5405 4Schering Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings 5401 1Schering Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings 5401 2
... Australia, March 12, 2007: Progen Industries Limited,(ASX: PGL; NASDAQ: ... liver cancer data has been accepted for late breaking ... the Liver,(EASL). Progen will also be presenting the results ... Cancer Research (AACR),Annual Meeting 2007. , ,In expectation ...
... Md., March 13, 2007--New evidence suggests that if ... risk of,cardiovascular disease. Researchers from the long-standing,Framingham Heart ... and Blood Institute (NHLBI) of the National Institutes ... were more,likely to avoid developing high blood pressure, ...
Other Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 2Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 3
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: